No Data
No Data
Express News | Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Aurinia Pharmaceuticals (AUPH Quick QuoteAUPH - Free Report) shares ended the last trading session 6.6% higher at $5.86. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.9% gain over the past four weeks.
ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM
One of Company's Largest and Longest-Standing Shareholders Urges Board to Accept Director Resignations Announces Intentions to Maintain Vigilance and Continue Actions to Restore Shareholder Value ILJIN SNT Co., Ltd.
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum:
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Most Popular Amongst Retail Investors Who Own 54% of the Shares, Institutions Hold 35%
Aurinia Pharmaceuticals: Four Directors Received Less Than Majority Support at Annual Meeting
Aurinia Pharmaceuticals: Four Directors Received Less Than Majority Support at Annual Meeting